(0) Transaction Will Accelerate Global Growth of Mobidiag s Differentiated Molecular Platform, which Offers Ease of Use, Multiplex Capability and Rapid Turnaround Time
Hologic, Inc. (Nasdaq: HOLX), a global leader in women s health, announced today that it has signed a definitive agreement to acquire Mobidiag Oy, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation, for an enterprise value of approximately $795 million. This includes a cash payment of approximately $714 million (€600 million) for Mobidiag s equity, and net debt of approximately $81 million. Acquiring Mobidiag will further strengthen our international and diagnostics businesses by enabling us to expand into the large, fast-growing acute care adjacency with a near-patient testing solution that offers ease of use, multiplex capability and rapid turnaround time, said Jan Verstreken, group president, international at Hologic. We believe that
Mobidiag to Be Acquired by Hologic, Innovator in Women s Health Diagnostic Testing, for Approximately €668 Million pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.